



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, March 19, 2025
Minutes approved by the board on April 16, 2025

Web link to the meeting video: <https://youtu.be/NR6Hznggs-I>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20250319-PDAB-document-package.pdf>

Call to order and roll call: Chair Shelley Bailey called the meeting to order at 9:02 a.m. and roll was called.

Board members present: Chair Shelley Bailey, Vice Chair Amy Burns, Dan Hartung, Lauri Hoagland, Dan Kennedy, Chris Laman, John Murray

Absent: Robert Judge

Declaration of conflict of interest and meetings with entities or individuals related to board activities: John Murray and Dan Hartung made statements. View at video minute [00:00:47](#).

Approval of board minutes: Chair Bailey asked for a motion and second to approve the board minutes as shown on [Pages 3-6](#) of the agenda materials. Dan Kennedy made a motion to approve the minutes and John Murray provided a second. View at video minute [00:02:18](#).

MOTION to approve the March 19, 2025, minutes

Board Vote:

Yes: Lauri Hoagland, Dan Kennedy, Chris Laman, John Murray, Vice Chair Amy Burns, Chair Shelley Bailey

No: None

Abstain: Dan Hartung

Absent for the vote: Robert Judge

Motion passed 6-0

Executive director's program update: Ralph Magrish, executive director, Oregon Prescription Drug Affordability Board & Drug Price Transparency Program, provided a program update. View the video at minute [00:03:29](#).

Legislative update: Jesse O'Brien, Division of Financial Regulation (DFR) policy manager, provided an update on prescription drug-related bills proposed in the Oregon Legislative session as shown on [Pages 6-9](#) of the agenda materials. View the video at minute [00:07:32](#).

Public comment: Chair Bailey called on the people who signed up in advance to speak to the board: Dharia McGrew, PhRMA; Tiffany Westrich-Robertson, Patient Inclusion Council/AiArthritis, EACH; and John Mullen, Oregon Coalition for Affordable Prescriptions. The



board received eight written comments, which are posted on the [PDAB website](#). View the speakers at video minute [00:11:39](#).

Board review of request for information forms: Cortnee Whitlock, senior policy analyst, continued last month's discussion on the request for information surveys, which will be sent to the following: patients, caregivers, and advocacy groups; individuals with scientific training; safety net providers; pharmacy benefit managers; and pharmaceutical manufacturers. View the draft forms on [Pages 10-25](#) of the agenda materials. View at video minute [00:23:15](#).

Board review of request updated carrier data call template: The board discussed the data call template, which will be sent to insurance carriers. View the template on [Pages 26-45](#) of the agenda materials. View the discussion at video minute [00:31:03](#).

Board review of data sets and OAR 925-200-0010 criteria to select subset of drugs for affordability reviews: Cortnee Whitlock led board members in a discussion about the data sets, based on criteria in [OAR 925-200-0010](#). View information on [Pages 46-50](#) of the agenda materials. View the [data dashboard](#) on the [prescription drug data](#) page. The board voted on a subset list of prescription drugs for affordability review. The list is posted on the [PDAB affordability review page](#) and included in the minutes. View the discussion and vote beginning at video minute [00:40:35](#).

MOTION to approve the prescription drug subset list for affordability reviews as discussed by the board today.

Motion made by Amy Burns with a second by Lauri Hoagland.

Board vote:

Yes: Dan Hartung, Lauri Hoagland, Dan Kennedy, Chris Laman, John Murray, Vice Chair Amy Burns, Chair Shelley Bailey

No: None

Absent for the vote: Robert Judge

Motion passed 7-0

Board review and discussion of insulin drugs for affordability reviews: The board began discussion of insulin drugs based on criteria in [OAR 925-200-0010](#). View the [data dashboard](#) on the [prescription drug data](#) page. View the discussion at video minute [02:30:36](#).

Announcements: Chair Bailey announced the next meeting will be April 16, 2025, at 9 a.m. View at video minute [02:51:09](#).

Adjournment: Chair Bailey adjourned the meeting at 12 p.m. with all board members in agreement. View at minute [02:51:22](#).



Subset list of 2023 prescription drugs for affordability reviews, approved by the board March 19, 2025

| Therapy class | Proprietary name(s) | Non-proprietary name |
|---|---------------------|---|
| Migraine Products | Ajovy | Fremanezumab-vfrm |
| Neuromuscular agents | Botox | Onabotulinumtoxin/Botulinum Toxin |
| Dermatologicals | Cosentyx | Cosentyx/ Cosentyx Senoready Pen/ Cosentyx Sensoready Pen(2)/secukinumab |
| Digestive Aids | Creon | Pancrelipase/Lipase/Protease/Amylase |
| Dermatologicals | Dupilumab | Dupilumab |
| Anticoagulants | Eliquis | Apixaban |
| Migraine Products | Emgality | Galcanezumab |
| Cardiovascular agents – misc. | Entresto | Sacubitril/Valsartan |
| Analgesics – anti-inflammatory | Humira | Humira/Humira Pen/ Humira (CF) Pen/Adalimumab |
| Antineoplastics and adjunctive therapies | Ibrance | Palbociclib |
| Antidiabetics | Jardiance | Empagliflozin |
| Antidiabetics | Mounjaro | Tirzepatide |
| Migraine Products | Nurtec | Rimegepant/rimegepant sulfate |
| Psychotherapeutic and neurological agents – misc. | Ocrevus | Ocrelizumab |
| Antivirals | Odefsey | Emtricitabine/Rilpivirine/Tenofovir Alafenamide |
| Antidiabetics | Ozempic | Semaglutide |
| Antineoplastics and adjunctive therapies | Perjeta | Pertuzumab |
| Analgesics – anti-inflammatory | Rinvoq | Upadacitinib |
| Antidiabetics | Rybelsus | Semaglutide |
| Dermatologicals | Taltz | Ixekizumab |
| Antiasthmatic and bronchodilator agents | Trelegy | Trelegy Ellipta/Fluticasone Umeclidin vilanter/Fluticasone Umeclidinum vilanterol |
| Dermatologicals | Tremfya | Guselkumab |
| Antidiabetics | Trulicity | Dulaglutide |
| Migraine Products | Ubroelvy | Ubrogepant |
| Antineoplastics and adjunctive therapies | Verzenio | Abemzciclib |
| Antipsychotics/antimanic agents | Vraylar | Cariprazine/Cariprazine HCl |
| Anticoagulants | Xarelto | Rivaroxaban |